Literature DB >> 8139023

In vivo evolution of c-rel oncogenic potential.

R Hrdlicková1, J Nehyba, E H Humphries.   

Abstract

The c-rel proto-oncogene belongs to the NF-kappa B/rel and I kappa B gene families, which regulate several inducible processes, including self-defense/repair and embryogenesis. Transduction of the c-rel transcription factor by the avian retrovirus resulted in the formation of a highly oncogenic virus, reticuloendotheliosis virus strain T (REV-T), that encodes the oncogene v-rel. To examine the oncogenic potential of c-rel, we inserted it into a REV-T-based retroviral vector, rescued virus [REV-C(CSV)], and infected 1-day-old chicks. All birds developed tumors, and all cell lines established from REV-C-induced tumors expressed c-rel proteins that lacked C-terminal sequences. These proteins, responsible for both in vivo and in vitro cell proliferation, were apparently selected for their oncogenic potential. In order to examine the cooperation of C-terminal deletions with other oncogenic alterations in vivo, point mutations present in the N-terminal and middle regions of v-rel were analyzed by a similar protocol. The data obtained support four conclusions. (i) c-rel proteins bearing any of three single-amino-acid mutations present in the N-terminal portion of v-rel were sufficiently oncogenic to induce tumor development in the absence of additional mutations. (ii) Combining a mutation from the N-terminal region of v-rel with a deletion of the C-terminal sequences of c-rel increases the oncogenicity of the protein in an additive manner. (iii) Mutations present in the middle of v-rel cooperated synergistically with C-terminal deletions to produce highly transforming viruses. (iv) Deletion of c-rel produced a variety of transforming rel proteins with sizes that extended from 42 to 65 kDa. The most frequently isolated rel deletion was 62 kDa in size. To examine the basis for the selection of different rel mutants, their ability to induce immunoregulatory surface receptors was analyzed. The data revealed a correlation between the induction capacity of these mutants and their corresponding contribution to in vivo tumorigenic potential. Moreover, an analysis of the subcellular localization of different rel proteins revealed an inverse correlation between the size of the protein and the proportion in the nucleus of lymphoid cells.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8139023      PMCID: PMC236714     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  70 in total

1.  A protein kinase-A recognition sequence is structurally linked to transformation by p59v-rel and cytoplasmic retention of p68c-rel.

Authors:  G Mosialos; P Hamer; A J Capobianco; R A Laursen; T D Gilmore
Journal:  Mol Cell Biol       Date:  1991-12       Impact factor: 4.272

2.  Rate and mechanism of nonhomologous recombination during a single cycle of retroviral replication.

Authors:  J Zhang; H M Temin
Journal:  Science       Date:  1993-01-08       Impact factor: 47.728

3.  Differential pp40I kappa B-beta inhibition of DNA binding by rel proteins.

Authors:  J A Diehl; T A McKinsey; M Hannink
Journal:  Mol Cell Biol       Date:  1993-03       Impact factor: 4.272

Review 4.  NF-kappa B and Rel: participants in a multiform transcriptional regulatory system.

Authors:  M Grilli; J J Chiu; M J Lenardo
Journal:  Int Rev Cytol       Date:  1993

5.  Transformation by the vRel oncoprotein requires sequences carboxy-terminal to the Rel homology domain.

Authors:  S Sarkar; T D Gilmore
Journal:  Oncogene       Date:  1993-08       Impact factor: 9.867

6.  B cell lymphoma-associated chromosomal translocation involves candidate oncogene lyt-10, homologous to NF-kappa B p50.

Authors:  A Neri; C C Chang; L Lombardi; M Salina; P Corradini; A T Maiolo; R S Chaganti; R Dalla-Favera
Journal:  Cell       Date:  1991-12-20       Impact factor: 41.582

7.  v-Rel and c-Rel are differentially affected by mutations at a consensus protein kinase recognition sequence.

Authors:  G Mosialos; T D Gilmore
Journal:  Oncogene       Date:  1993-03       Impact factor: 9.867

8.  The c-rel protooncogene product represses NF-kappa B p65-mediated transcriptional activation of the long terminal repeat of type 1 human immunodeficiency virus.

Authors:  S Doerre; P Sista; S C Sun; D W Ballard; W C Greene
Journal:  Proc Natl Acad Sci U S A       Date:  1993-02-01       Impact factor: 11.205

9.  Rel-associated pp40: an inhibitor of the rel family of transcription factors.

Authors:  N Davis; S Ghosh; D L Simmons; P Tempst; H C Liou; D Baltimore; H R Bose
Journal:  Science       Date:  1991-09-13       Impact factor: 47.728

10.  Variations in the cytoplasmic region account for the heterogeneity of the chicken MHC class I (B-F) molecules.

Authors:  L B Møller; J Kaufman; S Verland; J Salomonsen; D Avila; J D Lambris; K Skjødt
Journal:  Immunogenetics       Date:  1991       Impact factor: 2.846

View more
  16 in total

1.  A novel interferon regulatory factor (IRF), IRF-10, has a unique role in immune defense and is induced by the v-Rel oncoprotein.

Authors:  Jirí Nehyba; Radmila Hrdlicková; Joan Burnside; Henry R Bose
Journal:  Mol Cell Biol       Date:  2002-06       Impact factor: 4.272

2.  CAPERalpha is a novel Rel-TAD-interacting factor that inhibits lymphocyte transformation by the potent Rel/NF-kappaB oncoprotein v-Rel.

Authors:  Jui Dutta; Gaofeng Fan; Céline Gélinas
Journal:  J Virol       Date:  2008-08-27       Impact factor: 5.103

3.  Loss of IkappaB alpha-mediated control over nuclear import and DNA binding enables oncogenic activation of c-Rel.

Authors:  S Sachdev; M Hannink
Journal:  Mol Cell Biol       Date:  1998-09       Impact factor: 4.272

4.  A rearranged EP300 gene in the human B-cell lymphoma cell line RC-K8 encodes a disabled transcriptional co-activator that contributes to cell growth and oncogenicity.

Authors:  Michael R Garbati; Ryan C Thompson; Leila Haery; Thomas D Gilmore
Journal:  Cancer Lett       Date:  2011-01-12       Impact factor: 8.679

5.  Evolution of the oncogenic potential of v-rel: rel-induced expression of immunoregulatory receptors correlates with tumor development and in vitro transformation.

Authors:  J Nehyba; R Hrdlicková; E H Humphries
Journal:  J Virol       Date:  1994-04       Impact factor: 5.103

6.  The relocalization of v-Rel from the nucleus to the cytoplasm coincides with induction of expression of Ikba and nfkb1 and stabilization of I kappa B-alpha.

Authors:  R Hrdlicková; J Nehyba; A Roy; E H Humphries; H R Bose
Journal:  J Virol       Date:  1995-01       Impact factor: 5.103

7.  Alternatively spliced telomerase reverse transcriptase variants lacking telomerase activity stimulate cell proliferation.

Authors:  Radmila Hrdlicková; Jirí Nehyba; Henry R Bose
Journal:  Mol Cell Biol       Date:  2012-08-20       Impact factor: 4.272

8.  PEST-dependent cytoplasmic retention of v-Rel by I(kappa)B-alpha: evidence that I(kappa)B-alpha regulates cellular localization of c-Rel and v-Rel by distinct mechanisms.

Authors:  E M Rottjakob; S Sachdev; C A Leanna; T A McKinsey; M Hannink
Journal:  J Virol       Date:  1996-05       Impact factor: 5.103

9.  Mouse mammary tumor virus c-rel transgenic mice develop mammary tumors.

Authors:  Raphaëlle Romieu-Mourez; Dong W Kim; Sang Min Shin; Elizabeth G Demicco; Esther Landesman-Bollag; David C Seldin; Robert D Cardiff; Gail E Sonenshein
Journal:  Mol Cell Biol       Date:  2003-08       Impact factor: 4.272

10.  Mapping of a serine-rich domain essential for the transcriptional, antiapoptotic, and transforming activities of the v-Rel oncoprotein.

Authors:  C Chen; F Agnès; C Gélinas
Journal:  Mol Cell Biol       Date:  1999-01       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.